The vaccine and a dominant variant may not match this year, which combined with low vaccine rates could make for a severe flu ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

A Fredericton-based pharmacist says people are still showing up to get vaccinated for influenza, despite recent news that ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

Flu vaccines are crucial tools in protecting public health by reducing the risk of influenza illness and its complications.

Health experts warn this flu season could be unusually severe, with early spread and concerning H3N2 strain activity across ...

Study shows high-dose vaccines work better for older adults while cell-based versions benefit younger people as respiratory ...

Each year, as Americans roll up their sleeves for their annual flu shot, they might be surprised to learn their protection ...

Caption: Fredericton pharmacist says that despite the possible mismatch between evolving flu strain H3N2 and this year's flu vaccine, getting the shot can activate the immune system to be on alert.